Business Description
Ocata Therapeutics Inc
ISIN : US67457L1008
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.31 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.44 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.9 | |||||
Beneish M-Score | -2.92 |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -46.1 | |||||
3-Year EBITDA Growth Rate | 18.5 | |||||
3-Year EPS without NRI Growth Rate | -36.6 | |||||
3-Year FCF Growth Rate | -7 | |||||
3-Year Book Growth Rate | -69.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.99 | |||||
Quick Ratio | 6.99 | |||||
Days Payable | 10 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.6 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.15 | |||||
Operating Margin % | -13915.92 | |||||
Net Margin % | -12414.43 | |||||
ROE % | -482.67 | |||||
ROA % | -143.95 | |||||
ROC (Joel Greenblatt) % | -3028.33 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 169.49 | |||||
PS Ratio | 1694 | |||||
PB Ratio | 26.06 | |||||
EV-to-Revenue | 1652.68 | |||||
Earnings Yield (Greenblatt) % | -7.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ocata Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.62 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 0.12 - 8.17 | ||
Shares Outstanding (Mil) | 42.3 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ocata Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ocata Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ocata Therapeutics Inc Frequently Asked Questions
What is Ocata Therapeutics Inc(FRA:T2N1)'s stock price today?
When is next earnings date of Ocata Therapeutics Inc(FRA:T2N1)?
Does Ocata Therapeutics Inc(FRA:T2N1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |